Glaukos logo

Glaukos

GKOS | NYSE
Chart Builder DCF Calculator
$244.88
-$0.84 (-0.34%)
At close: Nov 16, 2026, 4:00 PM ET
$246.00
+$1.12 (+0.46%)
After-hours: Nov 16, 2026, 7:33 PM ET
-0.34%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
44.9
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #392/1021 (Top 38%)

Key Statistics

Market Data

Market Cap $14.5B
1D Range
242.31 250.61
52W Range
88.40 250.61

Valuation (TTM)

PE -83.29
PB 20.21
EV/EBITDA -115.01

Valuation (NTM)

Forward PE 366.75
Forward PEG 0.46
Price Target $225.00
Loading financial charts...

Profile

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. T...

Sector Healthcare
Employees 1,094
IPO Date Jun 25, 2015
Fiscal Year January - December

Latest News

Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction

18 days ago · fool.com

Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket

19 days ago · benzinga.com

Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

19 days ago · seekingalpha.com

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates

19 days ago · zacks.com

Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics

19 days ago · zacks.com

Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
Glaukos Q3 Earnings Call Highlights

19 days ago · marketbeat.com

Glaukos Q3 Earnings Call Highlights
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

1 month ago · zacks.com

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
Glaukos: The Second J-Code Rewrites The Risk Math

1 month ago · seekingalpha.com

Glaukos: The Second J-Code Rewrites The Risk Math
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

1 month ago · zacks.com

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

1 month ago · benzinga.com

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Earnings

Latest Earnings
Oct 28, 2026
EPS
$0.47
Beat +587.75%
REV
$211.03M
Beat +25.58%
Next Earnings
Feb 16, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
12
Consensus
Buy
Price Target
$240.00
Downside
-1.99%
Buy (11)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.